NextCell Pharma AB EBIT

The latest EBIT for NXTCL.ST is $-45M as of June 2026. That compares with $-40M in the prior-year period — down 13.1% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside NextCell Pharma AB's historical trend and sector peers before judging valuation or financial health.

Over the past year, NXTCL.ST's EBIT moved from $-40M to $-45M — a 13.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NextCell Pharma AB's operating scale or balance-sheet position.

Against Healthcare companies, NXTCL.ST currently prints $-45M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at NextCell Pharma AB's growth, margins, and balance sheet.

A EBIT figure of $-45M for NXTCL.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting NXTCL.ST's EBIT ($-45M), review year-over-year change from $-40M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.